



HYMOVIS[®] Demonstrates Superior Biomechanical Lubricating Properties

HYMOVIS[®] has exceptional lubricating properties in moving cartilage to a low-friction regime. The study provides a unifying framework to evaluate the potential clinical efficacy of injectable hyaluronic acid therapies

PARSIPPANY, NJ., March 22, 2017 - Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA) - based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces new data will be presented at the Annual Meeting of the Orthopaedic Research Society (ORS) in San Diego, CA, March 19-22, 2017.

Scientists from Fidia Farmaceutici S.p.A. and the research group led by Dr. Lawrence Bonassar, Professor at the Meinig School of Biomedical Engineering at Cornell University evaluated the *in vitro* rheological and tribological properties of six commercial HA products used for the treatment of pain in osteoarthritis (OA) of the knee. “In our research, we demonstrated that there are clear differences in the lubricating abilities of this cohort of HA products. HYMOVIS[®] is an exceptional viscous lubricant in moving cartilage to a low-friction regime, having superior biomechanical lubricating properties amongst all the HAs evaluated.” In addition, the study approach offers a novel method to evaluate the potential clinical efficacy of injectable hyaluronic acid therapies that may be more sensitive than rheological measurements alone*.

This new data will be presented in the late breaking session of the Annual Meeting of the Orthopaedic Research Society (ORS) on Wednesday, March 22, 2017 (<http://www.ors.org/Transactions/63/2374.pdf>).

HYMOVIS[®] is a highly viscoelastic, non-crosslinked hydrogel bioengineered using a proprietary process that increases lubrication and shock absorption properties. This results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints. The formulation allows this unique molecule to recover its original structure, even after repetitive mechanical stress. Due to reversible hydrophobic interactions, the non-crosslinked HYMOVIS[®] has increased elasticity, viscosity and residence time in the joint.* Its unique molecular structure results in enhanced biomechanical properties and long-lasting efficacy, all in a convenient two-dose regimen.

About Fidia Pharma USA Inc.

Fidia Pharma USA Inc is a wholly-owned subsidiary of Italian pharmaceutical manufacturer Fidia Farmaceutici S.p.A., an established leader in the hyaluronic acid market segment. Fidia Pharma USA Inc. is focused on expanding Fidia’s position in the U.S. and Canadian market, while upholding the company’s mission to provide consumers with innovative products that offer quality, safety and performance. Fidia Pharma USA Inc. is headquartered in Parsippany, NJ. For more information, please visit www.fidiapharma.us.

About Fidia Farmaceutici S.p.A.

Fidia Farmaceutici S.p.A. is an Italian pharmaceutical company founded in 1946. It is a leader in research and marketing hyaluronic acid-based products, with several applications in the biomedical field, such as rheumatology, orthopaedics, surgery, wound care, tissue repair and dermo-aesthetics. Fidia Farmaceutici is part of the P&R Holding group. The company is located in Italy, with R&D facilities in Abano Terme (Padua) and Noto (Sicily). Fidia has more than 700 employees, and its revenue exceeds €250 million euros. Fidia Farmaceutici S.p.A.'s products are marketed in more than 100 countries, through wholly owned subsidiaries and a comprehensive network of international partnerships and distributors. Thanks to its investment in research, it has created a legacy of products with more than 600 patents to its name. For more information, please visit www.fidiapharma.com.

For more information, contact:

Fidia Pharma USA Inc.
Morris Corporate Center 1
Building C, 1st floor
300 Interpace Parkway
Parsippany, NJ 07054
1-973-507-5120
ckong@fidiapharma.us

HYMOVIS[®] is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics. HYMOVIS[®] is contraindicated in patients with known hypersensitivity to hyaluronate preparations or gram positive bacterial proteins or patients with infections/skin diseases in the area of the injection site/joint. The safety and effectiveness of HYMOVIS[®] has not been tested in pregnant women, nursing mothers or children. See package insert for full prescribing information including adverse events, warnings, precautions, and side effects at www.Hymovis.com.

HYMOVIS and HYADD 4 are registered trademarks of Fidia Farmaceutici S.p.A., Abano, Terme, Italy.
©2016 Fidia Pharma USA Inc., Parsippany, NJ, a wholly owned subsidiary of Fidia Farmaceutici S.p.A.
FID477-03.2017

*Preclinical studies may not be indicative of human clinical outcomes.

Rx Only
